Navigation Links
Perrigo Acquires UK OTC Store Brand Supplier
Date:1/9/2008

ALLEGAN, Mich., Jan. 9 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has acquired Galpharm Healthcare, Ltd. for $86 million in cash. Based in Barnsley, Yorkshire, United Kingdom, privately-held Galpharm is a leading supplier of over-the-counter (OTC) store brand pharmaceutical products sold by super markets, drug stores and pharmacies in the U.K. The acquisition is expected to add more than $55 million in sales annually and be accretive to earnings in the first year.

Perrigo Chairman and CEO Joseph C. Papa stated, "The acquisition of Galpharm further expands our global presence, complements our existing UK business and increases value for our shareholders. It also helps us meet the world's growing need for quality, affordable healthcare."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2007, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
2. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
3. Perrigo Company Announces Dividend Increase
4. Perrigo Company Will Release First Quarter Fiscal 2008 Results on November 1, 2007
5. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
6. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
7. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
8. Perrigo Company to Host Analyst Meeting on September 18, 2007
9. Perrigo Vice Chair Mori Arkin To Retire After 30 Years of Service
10. Jobson Medical Information LLC Acquires CenterWatch and New England IRB From Thomson Healthcare
11. Grubb & Ellis Healthcare REIT Acquires Park Place Office Park in Dayton, Ohio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... ... until January 15, 2017 to apply for a 2016/2017 California Casualty Thomas R. ... . Qualifying schools can receive up to $3,000. , The grant ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... in research and development, largely due to its potential for revolutionizing human disease ... (hMSCs) and human induced pluripotent stem cells (hiPSCs). , Both platforms have ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... released the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement has ... the world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms every ...
(Date:12/6/2016)... ... 2016 , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating to SpinLife, ... freedom to people who need help getting around. For some, advancing age has led ... of rehabilitation after an illness or accident. There is a wide variety of scooters, ...
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is ... natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO ... to create an organic spectrum of lights that simulates the look of a glare. ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Spain Glaucoma Surgery Devices Market Outlook to ... Surgery Devices Market Outlook to 2022", provides key market ... report provides value, in millions of US dollars, volume ... - Canaloplasty Micro Catheters and Glaucoma Drainage Devices. ... data for each of these market segements, and global ...
(Date:12/5/2016)...  Cornerstone Pharmaceuticals, Inc., a privately held, clinical-stage, ... Phase I trials evaluating its lead compound, CPI-613, ... of the American Society of Hematology (ASH) in ... two datasets show encouraging efficacy and safety results ... T-cell non-Hodgkin,s lymphoma (T-cell NHL), respectively, supporting the ...
(Date:12/5/2016)... , Dec. 5, 2016  Pennsylvania Physician General Dr. ... Alcohol Programs Gary Tennis today filled prescriptions ... Minnich,s Pharmacy in York to ... by Dr. Levine as a prescription to acquire naloxone ... "It,s important to remember that any Pennsylvanian can walk ...
Breaking Medicine Technology: